Clinical Report: Adoptive TIL Therapy for a Patient with Metastatic Melanoma and Well-Controlled HIV
Overview
This report presents the first known case of a patient with well-controlled HIV receiving tumor-infiltrating lymphocyte (TIL) therapy for metastatic melanoma. The patient tolerated the treatment with manageable toxicity and demonstrated an early partial response, highlighting the need for further research in this population.
Background
Melanoma is a leading cause of cancer-related mortality, with many patients experiencing resistance to current therapies. Individuals living with HIV have historically been excluded from clinical trials of adoptive cell therapies, raising concerns about their safety and efficacy. Understanding the interaction between HIV and TIL therapy is crucial for expanding treatment options for this vulnerable population.
Data Highlights
No numerical data available in the source material.
Key Findings
The patient had a history of rapidly progressive, BRAF-V600E mutant metastatic melanoma.
TIL therapy was administered after the patient failed multiple lines of treatment, including anti–PD-1 therapy.
The treatment was tolerated with expected toxicities, including grade 1 cytokine release syndrome.
A partial response was observed at day 44, with decreased pulmonary metastases.
CD4 counts fluctuated, but virologic suppression was restored by day 100.
Clinical Implications
This case suggests that TIL therapy can be safely administered to patients with well-controlled HIV, offering a potential treatment avenue for those with refractory metastatic melanoma. Clinicians should consider the inclusion of HIV-positive patients in future clinical trials to better understand the implications of TIL therapy in this population.
Conclusion
The successful administration of TIL therapy in this patient with well-controlled HIV underscores the need for further investigation into the safety and efficacy of cellular therapies in similar populations.
